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Abstract: Poststroke depression (PSD) is a common sequela of stroke associated with 
increased morbidity and mortality among stroke survivors. PSD has been associated with 
poorer rehabilitative outcomes, longer inpatient stays, inefficient use of medical resources, 
worsened cognitive decline, and increased suicidality. This article reviews the definition and 
proposed etiology of PSD as well as current and emerging evidence-based prevention, screening, 
and treatment modalities. The timely use of prevention and treatment techniques including 
pharmacologic and nonpharmacologic methods may improve treatment outcomes and enhance 
the quality of life in stroke patients.
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Introduction
According to a 2008 World Health Organization (WHO) report, stroke and other 
cerebrovascular diseases were the second leading cause of death in 2004, resulting in 
more than 5.7 million deaths and accounting for roughly 10% of deaths worldwide.1 
Individuals who survive this potentially deadly event are often left with significant 
physiologic and psychiatric complications. The psychiatric sequelae of stroke and cere-
brovascular disease include maladies such as anxiety,2 psychosis, posttraumatic stress 
disorder (PTSD),3 and poststroke depression (PSD).4 More specifically, PSD has been 
reported to have a prevalence of 25%–80% in stroke victims depending on the study 
instrument.5–8 In this article, we provide an up-to-date review of the etiology, diagnosis, 
treatment, and impact of PSD.
For an individual, the sequelae of stroke can be life-altering. A previously inde-
pendent person may now require others to perform the most basic of daily activities. 
Others may find themselves unable to perform their jobs or participate in their usual 
social activities. This significant loss of function can result in profound and debilitating 
depression. Additionally, research has shown that depression compounds the disabling 
effects of a stroke,9–12 worsens cognitive decline,13,14 and increases suicidality as well 
as overall morbidity and mortality.15–17
For society, the costs associated with PSD are tremendous. PSD is associated with 
poorer rehabilitative outcomes,18 longer inpatient rehabilitation stays, increased inpatient 
and outpatient medical utilization,19,20 and inefficient use of rehabilitation services.21 The toll 
of caring for individuals with PSD significantly impacts the community at large, but is felt 
most acutely by those providing the day-to-day care of stroke survivors. Many caregivers 
experience provider fatigue, social isolation, and mood symptoms.22–24 These widespread Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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costs to the survivor, their caregivers, and the community at large 
show the need for further research in this area and aggressive 
multidisciplinary treatment inclusive of all affected.
Defining PSD
A very wide range of PSD prevalence estimates exist in the 
current literature. This variability stems from the difficulty in 
assessment and diagnosis of depression in stroke survivors. Cur-
rently, there is no standardized, widely accepted measure of PSD. 
The heterogeneity of cognitive and functional deficits in stroke 
survivors makes standardized measures difficult. Prevalence 
estimates in this population may be over- or underdiagnosing 
this disorder due to the difficulty in distinguishing depressive 
symptoms from stroke sequelae.25 The most appropriate means 
of diagnosing PSD have remained uncertain since the mid-
twentieth century when it was first understood as a significant 
complication of stroke. The heterogeneous symptoms compris-
ing PSD have been a continual source of controversy in field 
of geriatric psychiatry given a lack of consensus on etiology, 
pathogenesis, and course in stroke survivors.26
There are four methodological approaches to the diagnosis 
of PSD:27 the inclusive approach,28 the etiologic approach,29 
the substitutive approach,30 and the exclusive approach.31 
Under the inclusive approach, all depressive symptoms would 
be considered at face value regardless of underlying patho-
genesis.28 Critics of this approach point to overdiagnosis of 
depression in patients where neurovegetative symptoms are 
better categorized as stroke symptoms. The etiologic approach 
would count depressive symptoms only if the clinician 
believes the symptom is related to organic depression and not 
stroke-related deficits.29 The substitutive approach uses other 
psychological symptoms of depression in place of neuroveg-
etative symptoms.30 Under this paradigm, neurovegetative 
symptoms are excluded because of the confounding vegeta-
tive symptoms associated with stroke. Finally, the exclusive 
approach only includes symptoms more prevalent in depressed 
versus nondepressed stroke survivors.31
Etiology of PSD
As is the case with nonstroke-related depression, the two 
primary sources of pathology in the development of PSD 
are biological and psychosocial. In the following section, 
we explore the evidence supporting both the biologic and 
psychosocial causes of this disorder.
Biological evidence
One would not be reading this article were it not for the strong 
association between the decidedly biologic phenomenon of 
stroke and the development of depression. Alexopoulos et al32 
outlined the following four areas of clinical evidence support-
ing the biologic hypothesis of PSD: 1) the increased preva-
lence of depression in patients with hypertension, diabetes, 
and coronary artery disease,33–35 2) the increased prevalence 
of depression among patients after stroke,36,37 3) the strong 
association of late-onset depression and the increased fre-
quency of silent stroke and white matter hyperintensities,38–41 
and 4) the rare association of family history of mood disorders 
in the context of silent stroke.42
The development of depression is more likely after 
stroke compared to any other physical disability.43 Research-
ers since the 1970s have proposed various mechanisms by 
which ischemic insult to certain areas of the brain results in 
depressed mood.44–47 Early hypotheses posit that ischemic 
insults to neural circuits of mood regulation, specifically left 
frontal subcortical circuits, result in depletion of biogenic 
amines and contribute to symptoms of depression.48,49 The 
association between ischemic lesions in the frontal lobe and 
depression is strongest early in the poststroke period, but 
this association appears to wane over time.46 Perhaps, this 
temporal association represents adjustment disorder with 
depressed mood in the early phase of recovery that resolves 
after the patient regains some level of function.
Some authors have suggested that the significant physical 
disability associated with stroke likely contributes to depres-
sive symptoms in poststroke patients. However, early 
research found no significant difference in the severity of 
depression between groups of elderly patients with chronic 
disability due to stroke and a matched control group with 
extracerebral disorders.50 Subsequently, research has shown 
PSD to develop even in patients with anosognosia.51,52 
Patients with anosognosia are unaware of physical deficits 
associated with their stroke yet exhibit depressive symptoms 
similar to patients with equivalent levels of disability. Even 
in the absence of disability, patients with ischemic insults to 
striatofrontal circuits demonstrate higher rates of depression 
compared to patients with ‘silent’ infarcts.32,38,40 This evidence 
supports the model of PSD as having at least an aspect that is 
primarily biologic despite early research to the contrary.
Psychosocial evidence
Multiple studies have attempted to localize a lesion consistent 
with PSD, but recent literature does not support discrete local-
ized ischemia as the sole cause of depressive symptoms.53,54 
The severity of depression and the prevalence of depressive 
symptoms after stroke have been found to be comparable to 
other illnesses with equivalent levels of disability.6,55 In fact, Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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a systematic review by Carson et al found no increased risk 
of depression after stroke based on the location of a brain 
lesion over time.53 This evidence contradicts the evidence 
presented demonstrating an association between frontal 
lesions and the development of early depression. Studies 
differ in conclusions based on when subjects are sampled for 
symptoms. Although earlier symptoms have been associated 
with localization of brain lesions, subjects sampled more than 
1 year after stroke show no such association.
Similar to nonstroke-related depression, one is able to 
predict the development of PSD using a number of psycho-
social factors.56,57 Kendler found that stressful life events, 
genetic factors, a previous history of major depressive dis-
order (MDD), and neuroticism contributed equally to the 
development of depression in stroke and nonstroke patients.56 
Functional disability after stroke appears to be the strongest 
risk factor for developing PSD. More than 15 articles found 
disability to be the strongest predictor of PSD,55,58,59 while 
just as many studies failed to find this association.58,60 Singh 
et al found that an important predictor of the development of 
PSD immediately poststroke was localization of the lesion 
while at 3 months severity of disability became significantly 
more predictive than lesion location.61
If the etiology of PSD were purely biological, resulting 
from brain lesions secondary to stroke, the development of 
PSD should not be influenced by prior psychiatric history 
or life experience, yet clinical studies have indeed found 
these factors to be important in the development of PSD. 
According to Whyte and Mulsant, 8 of 14 studies showed past 
  psychiatric history to be a risk factor in the development of 
PSD.58 Family history has also been shown to be a risk factor 
in the development of PSD.62–65 Further evidence indicates 
that personality disorders, social isolation, and poor familial 
support predispose individuals to developing depression 
after stroke.59,63,64,66,67 Proponents of the biologic hypothesis 
of PSD suggest that evidence of past psychiatric history, 
family history, and premorbid-functioning-associated risk 
does not necessarily contradict the biologic underpinnings 
of this disorder but serve as markers of susceptibility to a 
uniquely biologic process.
As can be seen from the preceding discussion, the data 
in this area are voluminous, contradictory, and indecisive 
regarding the degree to which biologic and psychological 
factors contribute to the development of PSD. On the basis 
of this evidence, PSD is most likely a multifactorial disorder. 
Minimizing or marginalizing the significant psychological 
stress and trauma associated with the acute development 
of disability associated with stroke would be ill advised, 
while the evidence indicates that particular lesion locations 
are strongly associated with the development of PSD in the 
early poststroke period. Like many other diseases involving 
the brain, this disorder might be best characterized by the 
stress–diathesis model or the two-hit hypothesis where a 
genetic or psychological predisposition to depression confers 
an increased susceptibility to the biological and psychiatric 
sequela of stroke. The degree to which these biological and 
psychological factors confer increased risk to an individual 
remains poorly understood.
Prevention and diagnosis
Prevention of PSD begins with the prevention of stroke. 
Annually, in the United States, approximately 610,000 people 
suffer stroke for the first time.68 Major modifiable risk factors 
for stroke include hypertension, diabetes, cigarette smoking, 
and hyperlipidemia.69 Despite widespread acknowledgment 
of these risk factors, stroke remains the third leading cause 
of death in the United States.68 Primary care physicians and 
mental health providers should be vigilant in monitoring blood 
pressure, cholesterol, and glucose control while encouraging 
smoking cessation. Family history is vitally important to prop-
erly assess the risk factors for stroke and depression. A family 
history of early-onset stroke or depression should result in 
earlier and more aggressive prevention strategies.
At the present time, there is little evidence to support the 
prophylactic treatment of stroke patients with antidepressant 
medications. In a review of 14 clinical trials, pharmacotherapy 
showed no clear effect in preventing PSD, but psychotherapy 
did show a statistically significant, though small, effect.70 
To date, only one study has shown a significant benefit using 
an antidepressant (sertraline) as a prophylaxis against PSD. 
This study was a double-blind, placebo-controlled study of 
155 patients over a 12-month period, and it showed 10% 
PSD in the treatment group and 30% in the placebo group.71 
The appropriate mechanisms for prevention remain unclear 
but given the limited downside to psychotherapy, such an 
approach seems a safe and appropriate course until further 
research is concluded.
Patients who suffer a stroke should be screened for symp-
toms of depression throughout their poststroke course. There 
is little consensus regarding the exact timing of PSD screen-
ing given the inherent heterogeneity of the disease etiology. 
Further complicating matters is the natural interindividual 
variability of stroke survivors. Despite this variability, there 
are some general principles evident in the current literature. 
In 2002, Whyte and Mulsant reviewed the prevalence of 
MDD after stroke based on the time since stroke.58 Peak in Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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symptoms occurred approximately 3–6 months after stroke 
with a subsequent 50% decline in prevalence by 1 year.58 
This finding suggests that screening should occur more 
frequently (eg, monthly) in the initial poststroke period and 
should continue at regular intervals (eg, annually) for any 
stroke survivor.
Several risk factors for PSD also appear to be strongly 
correlated to PSD symptom severity. These risk factors 
include the discrepancy between premorbid and poststroke 
physical functioning,72 a history of a psychiatric condi-
tion (eg, depression),63 female sex,61,64 location of CVA 
lesion,73 and reversal of social roles.74 Cognitive impairment 
secondary to stroke14,59 and communication difficulties due 
to aphasia also contribute to increased rate of PSD in elderly 
populations.14,75 Patients with limited social supports also 
have higher rates of depression after stroke.6,74 These risk 
factors coupled with a biologic predisposition to depres-
sion based on a family history increase the likelihood of 
disease development. Screening and evaluations for PSD 
should include these factors at a minimum in order to assess 
the likelihood of the disorder and the potential severity of 
symptoms. Individuals with either numerous risk factors for 
developing PSD and/or factors indicating a more severe case 
of PSD need increased monitoring, preferably by experienced 
professionals.
In addition to a careful history and evaluation of PSD 
risk factors, psychometric tests may also be useful in assess-
ment and monitoring. As indicated in the preceding section 
entitled, ‘defining PSD,’ the way one defines PSD determines 
the measures employed to diagnose the illness. Gianotti et al 
designed the poststroke depression rating scale (PS-DRS) 
in order to examine the phenomenology of PSD.76,77 This 
measure was developed to assess emotional, affective, and 
vegetative defects after stroke. Table 1 provides a list of 
items included in the PS-DRS. Their results demonstrated 
a high correlation between depression and disability but 
did not validate the addition of apathy, hyperemotionalism, 
and catastrophic reactions in determining the presence or 
absence of PSD.
There have been several measures validated for screening 
of major depressive symptoms (DSM-IV criteria) in stroke 
patients. The Beck depression inventory (BDI), hospital 
anxiety and depression scale (HADS), SCL-90, and Hamilton 
depression rating scale (HDRS) have all been validated in 
poststroke patients with good sensitivity and specificity.78 In 
a recent study by Healey et al the brief assessment schedule 
depression cards (BASDEC) were found to be the most 
accurate screening tools for PSD compared to the HADS and 
BDI (fast screen).79 Using the BASDEC will result in less 
false positives and more efficient screening and treatment 
of PSD patients.
All tests may not be valid for a given individual 
based on poststroke cognitive disability and language 
deficits. Researchers have developed assessments to adapt 
to the cognitive deficits suffered by many stroke survivors. 
Gordon and Hibbard developed the structured assessment 
of depression in brain-damaged individuals (SADBD).5 
This assessment only requires yes or no answers from par-
ticipants and also includes visual cue cards for patients with 
aphasiac symptoms. In general, this diagnostic tool has not 
been widely adopted because of a lack of a graded response 
or suitability in patients with severe comprehension difficul-
ties. Other researchers have developed measures that have 
been shown to be valid to detect depressive symptoms in 
aphasic stroke patients, namely, the stroke aphasic depression 
questionnaire (SADQ-10).80 It is important for providers to 
assess deficits in patients prior to administering screening 
questionnaires to ensure the validity of the test.
Once a patient is identified with depressive symptoms, 
there are few reliable predictors of treatment outcomes. Onset 
of depressive symptoms after stroke appears to be predictive 
of PSD duration and treatment outcome. Stroke survivors who 
develop depressive symptoms within hours after stroke have a 
better prognosis for resolution of depressive symptoms within 
1 year of onset.81,82 However, approximately 30% of patients 
develop PSD up to 6 months after stroke.83 Among patients who 
have delayed onset of depressive symptoms, Anderson et al 
found that patients developing depression 7 weeks after stroke 
had lower rates of spontaneous recovery.84
Prevention of disease should be the highest priority for 
physicians; however, when stroke occurs, providers should 
be vigilant for symptoms of depression. Although psycho-
metric tools are helpful in the diagnosis and treatment of PSD 
symptoms, a thorough history of premorbid risk factors is 
absolutely essential for guiding diagnosis and choosing the 
Table 1 Items included in the post stroke depression rating scale 
(PS-DRS)
Depressed mood
Guilt feelings
Thoughts of death or suicide
vegetative symptoms
Apathy and loss of interest
Anxiety
Catastrophic reaction
Hyperemotionalism
Anhedonia
Diurnal mood variationsPsychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
113
Treatment of PSD and psychiatric distress
most appropriate treatment modality. The timing of onset of 
PSD symptoms after stroke may indicate which patients are 
refractory to typical treatment as outlined in the following 
section.
Treatment of PSD
To treat or not to treat
Several reviews of this topic indicate that a large portion 
of providers are uncomfortable with prescribing an antide-
pressant, antipsychotic, or stimulant to an elderly patient 
after stroke.85 Conservative management of these patients is 
certainly not without merit. Many of these patients are on 
multiple medications, and the addition of yet another medi-
cation may have an unforeseen consequence such as a drug 
interaction. Additionally, there is an increased risk of bleeding 
associated with selective serotonin reuptake inhibitor (SSRI) 
and an increased risk of stroke associated with the long-term 
use of atypical antipsychotics.86 These risks should be care-
fully considered prior to prescribing such medications.
Some providers consider depression as a natural byproduct 
of significant physical disability after stroke that will eventu-
ally resolve over time as the patient adapts to his or her new 
disability. Research has shown, however, that the use of anti-
depressants can result in significant improvement of symptoms 
regardless of the physical disability. In a recent review of more 
than 50 studies, antidepressant medications were shown to 
be more effective than placebo for treatment of depressive 
symptoms in poststroke patients.87 Improvement of depres-
sive symptoms will generally result in improved functional 
recovery and rehabilitative outcomes.88 This evidence suggests 
that despite the potential risks, consideration should be given 
to pharmacotherapeutic interventions in PSD (Table 2).
Tricyclic antidepressant therapy
Tricyclic antidepressants (TCAs) have been shown to be 
efficacious in the treatment of PSD (Table 3). In 2000, 
a double-blind, randomized, placebo-controlled trial by 
Robinson et al demonstrated a significant decrease in Ham-
ilton depression scale (HAM-D) scores in patients treated 
with nortriptyline for 12 weeks compared to fluoxetine and 
placebo treatment groups.89,90 Additionally, patients treated 
with nortriptyline showed a decrease in anxiety symptoms 
and improved recovery of activities of daily living.89
There is little doubt that TCAs are effective in the treat-
ment of depressive symptoms; however, these drugs confer 
a therapeutic benefit as well as a significant clinical risk of 
side effects. Alpha-1-adrenergic blockade by TCAs may 
result in orthostatic hypotension, making patients prone to 
falls and thus intracranial hemorrhage. The affinity of TCAs 
for histaminergic receptors causes increased sedation which 
may decrease intellectual functioning – a poorly tolerated side 
effect in poststroke patients. Anticholinergic side effects of 
TCAs include urinary retention, dry mouth, and constipation. 
TCAs are also a type 1a antiarrhythmic which can result in 
QT prolongation and torsades de pointe. Stroke patients with 
likely coronary artery disease may be particularly susceptible 
to the arrhythmogenic effects of TCAs. These side effects are 
the primary reason that TCAs see limited use in both general 
practice and in the treatment of PSD.
SSRI therapy
The efficacy of a number of SSRIs for PSD have been studied 
over the past few decades. Most SSRIs have demonstrated 
minimal efficacy in the treatment of PSD, supporting the 
hypothesis of PSD as uniquely different from MDD. In five 
double-blind, placebo-controlled studies, sertraline and fluox-
etine were no better than placebo in treatment or prevention 
of PSD.71,91–94 The lengths of these studies are significant 
limitations as most only lasted for 12 weeks, possibly not 
providing enough time to observe a significant change in 
subjects. It is also important to note that while some studies 
show no improvement of poststroke depressive symptoms, 
many studies demonstrate functional improvement with the 
use of SSRI medications.88,95 Fruewald et al followed patients 
for additional time (18 months) and found improvements in 
depressive symptoms among those in the fluoxetine group 
with significant dropout in the placebo group.92 Of the SSRIs 
studied in the treatment of PSD, citalopram has shown the most 
benefit as demonstrated by symptom reduction on the BDI 
scale.84,96 Despite the mixed evidence regarding the efficacy of 
SSRIs in the treatment of PSD, they remain the recommended 
first-line pharmacotherapy for PSD given favorable side effect 
profile.97 Suggested treatment guidelines for PSD acknowl-
edge there is no evidence to suggest that SSRIs improve PSD 
Table  2  Current  evidence-based  treatments  for  post  stroke 
depression
Intervention Level of recommendation
Selective serotonin  
reuptake inhibitors
Moderate evidence of utility
Tricyclic antidepressants Moderate evidence of utility
Atypical antipsychotics evidence is lacking to make 
recommendation
Mood stabilizers evidence is lacking to make 
recommendation
Stimulant medications Moderate evidence of utility
Cognitive behavioral therapy Likely small net benefitPsychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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symptoms better than TCAs.97,98 However, given the unwanted 
side effects of TCAs, as outlined in the previous section, an 
SSRI should be considered first.
No medication is without potential adverse side effects. 
SSRIs are no exception. SSRI side effects include GI upset, 
diarrhea, insomnia (REM attenuation), headache, increased 
anxiety, sexual dysfunction, and increased suicidal ideation in 
young patients. Increased risk of bleeding resulting from 
inhibition of platelet aggregation caused by SSRIs is an 
important consideration for elderly stroke patients potentially 
on anticoagulation medications. Other adverse side effects 
include drug–drug interactions via cytochrome P450 inhibi-
tion. Fluvoxamine is a ‘pan inhibitor’ with significant effects 
on CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4.99 
All SSRIs have some level of CYP2D6 inhibition, but fluox-
etine and paroxetine are potent inhibitors of CYP2D6. Given 
the large number of medications metabolized at CYP2D6 and 
the frequency of polypharmacy in the elderly population, 
careful consideration of each addition or subtraction of 
medication is strongly suggested. Drug interactions can result 
in life-threatening toxicities or ineffective therapies despite 
being on a ‘standard dose’ of medication.
Atypical antipsychotics
Atypical antipsychotics are often used in the treatment of 
PSD patients to target symptoms such as mood lability and 
irritability. Although there are significant risks in long-term 
administration of this class of medications, short-term use 
may be helpful during the acute rehabilitation phase. Studies 
demonstrating the association between atypical antipsychotics 
and increased risk for stroke have been focused on elderly 
populations with prolonged antipsychotic use. All patients 
Table 3 Trials for the treatment of post stroke depression
Treatment  
studied
Author Type of  
trial
N Diagnostic  
criteria
Outcome  
measure
Trial length  
(weeks)
Time from stroke  
(months)
Treatment  
response
Placebo
Nortriptyline Lipsey  
et al90
RCT 34 DSM III  
Major  
Minor
HDRS  
ZSRDS
4–6 ,18 36%† 22%†
Robinson  
et al89
RCT 56 DSM Iv  
Major  
Minor
HDRS 12 ,6 63%‡ 23%‡
Fluoxetine Robinson  
et al89
RCT 56 DSM Iv  
Major  
Minor
HDRS 12 ,6 9% 23%
Wiart  
et al112
RCT 66 ICD-10  
Major
MADRS 6 ,6 63%‡ 33%‡
Fruehwald  
et al92
RCT 54 DSM Iv  
Major  
Minor
HDRS  
BDI
16  
72
,1 69.2%  
81.8%*
75% 
27.8%*
Choi-Kwon  
et al93
RCT 152 DSM Iv  
Major  
Minor
BDI  
Clinical  
STAS
16  
26
14 28.7%  
27.1%
15.5% 
14.7%
Sertraline Murray  
et al91
RCT 123 DSM Iv  
Major  
Minor
MADRS  
eDS
26 1–52 33.9% 42.6%
Citalopram Andersen  
et al84
RCT 66 DSM III  
Major  
Minor
HDRS  
MeS
16 4 65%† 15%†
Methylphenidate Grade  
et al101
RCT 22 DSM Iv  
Major  
Minor
HDRS  
ZSRDS
3 ,1 28%‡ 24%‡
Cognitive 
behavioral  
therapy
Lincoln  
et al106
Case  
series
19 DSM Iv  
Major  
Minor
BDI  
HADS
16 ,1 24%‡ NA
Lincoln &  
Flannaghan108
RCT 123 DSM Iv  
Major  
Minor
BDI 16 1 29% 13%
Notes: †P , 0.005; ‡P , 0.05; *P , 0.05, post-hoc exploratory analysis with significant placebo drop-out.
Abbreviations: RCT, double-blind randomized controlled trial; BDI, Beck Depression Inventory; DSM Iv, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition; 
HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; MADRS, Montogomery–Asberg Depression Rating Scale; MeS, Melancholia Scale; STAS, 
Spielberger Trait Anger Scale; ZSRDS, Zung Self Rating Depression Scale.Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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should be counseled on the risks of smoking and OCP use 
while on atypical antipsychotics as they may compound the 
risk of stroke. Providers should weigh the risks, benefits, 
alternatives, and precautions with both patients and caregivers 
prior to prescribing atypical antipsychotics in PSD patients.
Mood stabilizers
To our knowledge, there have been no human trials 
investigating the use of lithium or of other mood stabiliz-
ers in the treatment of PSD or related sequelae. Animal 
model studies, however, have indicated a limited role for 
the use of lithium in the treatment of mood lability and 
irritability following stroke. Yan et al.100 demonstrated that 
lithium reduces behavioral disturbances in rats poststroke 
and reported lithium as protective for ischemia-reperfusion 
injury resulting in improved grooming, spatial learning, and 
memory ability.58,100 Histologically, rats treated with lithium 
prior to CVA had decreased cell death in the hippocampal 
CA1 region.101 Other studies indicate that lithium may 
stimulate hippocampal neurogenesis via the extracellular 
signal-regulated kinase pathway.101
Stimulant medications
Stimulants have also shown some utility in the treatment of 
PSD and fatigue after stroke. Methylphenidate in particular 
has been shown to lower HAM-D scores in a randomized, 
controlled trial of PSD patients.102 Modafinil has shown 
efficacy in the treatment of poststroke fatigue, but research 
has yet to establish the optimal strategy for its use.103 
Although the exact mechanism of action for modafinil is not 
entirely understood, it differs from the mechanism of action of 
amphetamines. Preclinical evidence suggests that modafinil 
decreases GABA activity in the area of the ascending reticular 
activating system thus promoting arousal.104 Modafinil lacks 
the peripheral sympathomimetic effects associated with 
methylphenidate use and is generally not associated with 
aggressive behavior. Stimulant medications have also been 
associated with increased ability to participate in physical 
therapy after a stroke.105 Despite the benefit of increased 
energy and decreased perceived disability, some stimulant 
medications such as methylphenidate carry a side effect 
profile that may actually worsen the patients’ ability to par-
ticipate in therapy.106 Side effects of stimulant medications 
include rare instances of mania, psychosis, suicidal ideation, 
depression, and stroke. Considerable caution should be exer-
cised when weighing the risks and the benefits of stimulant 
use in poststroke patients as patients might be exquisitely 
sensitive to side effects of these medications. Given the 
increased sensitivity of this population, providers may con-
sider initiating treatment at a low dose and slowly titrating 
increases in medication to target neurovegetative symptoms. 
Additionally, these medications should be used in a targeted 
and short-term fashion.
Psychotherapy
There is mixed evidence regarding the efficacy of CBT in PSD 
patients. Several studies have demonstrated the efficacy of CBT 
in the treatment of depression in adults and elderly patients. 
A study by Lincoln et al found CBT to improve mood in a 
small study of 19 stroke patients with depression.107 Likewise, 
a study of 41 elderly patients with disabilities, some with stroke 
(n = 18), demonstrated significant improvement in depressive 
symptoms with brief CBT group therapy.108 However, a ran-
domized, controlled trial of CBT for the treatment of PSD in 
123 patients did not find CBT to be efficacious.109 There were 
significant limitations to this recent randomized trial including 
a small sample size possibly lacking enough power to detect 
a significant difference between groups, shorter duration of 
treatment than previous studies, and no prescreening of patients 
into various treatment modalities. Patients were randomly 
assigned to treatment groups from a stroke register instead of 
being referred by a clinician for CBT based on the patients’ 
wiliness and capacity to engage in the cognitive model. As with 
other therapies, it is difficult to fully assess the efficacy of CBT 
because of the heterogeneous nature of cognitive and motor 
deficits associated with strokes.
Other psychotherapy methods including problem-solving 
training and motivational interviewing have also been shown 
to improve mood after stroke but not specifically depres-
sive symptoms in PSD. In a randomized, controlled trial 
of more than 400 patients, Watkins et al demonstrated an 
overall mood improvement on the general hospital question-
naire (GHQ-28).110 Motivational interviewing showed no 
improvement in the functional recovery of patients. In 2007, 
Robinson et al published research indicating that patients 
undergoing problem-solving therapy after stroke had a sig-
nificantly lower incidence of depression over 12 months of 
treatment compared with placebo. However, this result was not 
statistically significant using an intention-to-treat analysis.111
Conclusion
Depression is a common psychiatric condition after stroke. 
Depression, like other psychiatric illnesses, compounds 
physical symptoms and contributes to increased morbid-
ity, mortality, and poor rehabilitative outcomes. Providers 
should be committed to stroke prevention strategies including Psychology Research and Behavior Management 2010:3 submit your manuscript | www.dovepress.com
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coordination with primary care providers regarding aggressive 
management of hypertension, diabetes, and other risk factors. 
For patients who have suffered a stroke, providers should 
regularly screen for symptoms of depression. Screenings 
should take a multifactorial approach given the heterogeneity 
of symptoms arising from a range of biopsychosocial factors. 
When treating PSD, it is recommended that providers care-
fully review the risks, benefits, and therapeutic alternatives 
with patients and their caregivers. Treatments should be tai-
lored to the patients’ symptom profile and their cognitive and 
physical deficits. Medications should be started slowly and 
titrated to the minimum dose needed to treat target symptoms 
of depression. Patients in this population are particularly 
sensitive to medication side effects and have increased risk 
of polypharmacy drug interactions while on multiple medi-
cations. Successful treatment of PSD symptoms improves 
treatment outcomes, enhances quality of life, and ultimately 
decreases morbidity and mortality in stroke patients.
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